Moscow announces advanced trials for new COVID-19 vaccine
MOSCOW — The mayor of Moscow invited residents Wednesday to join trials of a coronavirus vaccine that Russia approved for use earlier this month in what officials described as a breakthrough on par with the Soviet Union's launch of the world's first satellite in 1957.
The world's first vaccine against the coronavirus to receive a government goahead has caused unease among international medical experts, who called Russia' s fast-tracked approval and failure to share any data supporting claims of the vaccine's efficacy a major breach of scientific protocol.
Scientists around the world say any widely-used vaccine should first be tested in advanced trials involving tens of thousands of people to prove it is safe and effective before being licensed.
In his invitation to the Russian capital' s re siden ts, Moscow Mayor Sergei Sobyanin appeared to announce those kind of broad studies would be launched soon. He said the “post-registration research” will last six months and involve 40,000 people.
So by an in encouraged Moscow residents to sign up, arguing that the vaccine was based on longtime previous research and proven to be safe.
“We all were eager to see the creation of a vaccine, and now we have it,” Sobyanin said. “Now, Moscow residents have a unique chance to become the main participants in clinical research that will help defeat the coronavirus.”
Scientists at the World Health Organization said last week that although they had begun discussions with Russia about i ts vaccine, they had not yet received any detailed data about it.
In announcing the vaccine's approval on Aug. 11, Russian President Vladimir Putin said one of his two adult daughters already had been inoculated with it. He said the vaccine underwent the necessary tests and was shown to provide lasting immunity to the coronavirus, although Russian authorities have offered no proof to back up claims of safety or effectiveness.
Experts warn that using an untested vaccine that has not yet proven to be safe or effective could ultimately undermine the response to the pandemic and cause more distrust among people about whether or not to be vaccinated.
As of Wednesday, Russia had reported a total of over 970,000 confirmed virus cases and 16,683 deaths. Russian officials have said the vaccine would initially be made available to high-risk groups, including medical workers and teachers before it comes to broad use.
The vaccine developed by the Gamaleya Institute in Moscow with assistance from Russia' s Defense Ministry uses a different virus — the common coldcausing adenovirus — that's been modified to carry genes for the “spike” protein that coats the coronavirus, as a way to prime the body to recognize if a real COVID19 infection comes along.